Related Experiment Video
Updated: Apr 16, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Functional and morphological myocardial changes in hepatitis C virus patients with end-stage liver disease
Dalia A Omran1, Noha Hosam E L Din Behairy, Khaled Serag Zakaria
1Endemic Medicine Department , Kasr El Ainy Hospital, Cairo University , Cairo , Egypt.
Insights
Delayed myocardial enhancement (DME) is common in liver transplant patients with end-stage liver disease. Cardiac magnetic resonance (CMR) shows DME extent correlates with left ventricular systolic function, aiding in assessing cardiovascular risk.
Area of Science:
- Cardiology
- Hepatology
- Radiology
Background:
- Cardiovascular complications are frequent in liver transplant recipients.
- Hepatitis C virus (HCV) patients with end-stage liver disease (ESLD) are at risk for cardiac issues.
Purpose of the Study:
- To evaluate myocardial changes in HCV patients with ESLD using cardiac magnetic resonance (CMR).
- To assess functional and morphological myocardial alterations in this patient group.
Main Methods:
- A cross-sectional study involving 84 patients with HCV-related ESLD.
- Utilized 2D-echocardiography and CMR to assess cardiac function and structure.
- Quantified the presence, distribution, and percentage of delayed myocardial enhancement (DME).
Main Results:
- All patients exhibited preserved global left ventricular (LV) systolic function.
- Grade I/II diastolic dysfunction was present in 96.4% of patients.
- Delayed myocardial enhancement (DME) was detected in 83.3% of patients, with a mean %DME of 19.5%.
- Significant negative correlation found between %DME and LV ejection fraction, cardiac output, cardiac index, and serum albumin levels.
Conclusions:
- Delayed myocardial enhancement (DME) is a prevalent finding in HCV patients with ESLD.
- The extent of DME significantly correlates with global left ventricular systolic function.
Background And Objectives:
Cardiovascular complications are common in liver transplant recipient. This study aims to evaluate functional and morphological myocardial changes in hepatitis C virus (HCV) patients with end-stage liver disease (ESLD) by cardiac magnetic resonance (CMR).
Methods:
This cross-sectional study included 84 patients with HCV-related ESLD. They were subjected to 2D-echocardiography and CMR. The presence, distribution, and percentage of delayed myocardial enhancement (DME) were estimated.
Results:
The mean Model for End-Stage Liver Disease score was 21.5 ± 6.3. In CMR, all patients showed good global left ventricular (LV) systolic function (mean ejection fraction = 66.5 ± 8.6%; range: 55-80) with normal wall thickness and motion. Left ventricle was mildly dilated in 25 patients (30%). Grade I and grade II diastolic dysfunction was detected in 81 patients (96.4%) with dilated left atrium in 25 patients (30%). Variable degrees of DME were detected in 70 patients (83.3%) with mean percentage of DME (%DME) being 19.5 ± 16% (range: 4-52). A significant negative correlation was found between %DME and LV ejection fraction (r = -0.7; p < 0.001), cardiac output (r = -0.5; p = 0.013), cardiac index (r = -0.5; p = 0.02), and serum albumin level (r = -0.5; p = 0.01). The %DME ≥19% was associated with 85.7% sensitivity and 85.7% specificity for detection of LV ejection fraction <60% as assessed by echocardiography (area under curve = 0.89; p = 0.001).
Conclusion:
DME with CMR is a common finding among patients with HCV-related ESLD. The extent of DME is significantly associated with global LV systolic function.
More Related Videos
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
04:49Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
Published on: June 14, 2024
Related Concept Videos
Myocarditis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hepatitis
Cardiomyopathy II: Dilated Cardiomyopathy
Myocarditis II: Clinical Features and Diagnostic Tests
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test